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Dendritic cells (DCs) are rare leukocytes that are uniquely potent in their recent
application to therapeutic cancer vaccines. Isolated DCs loaded with tumour
antigen ex vivo and administered as a cellular vaccine have been found to in-
duce protective and therapeutic anti-tumour immunity. In the present report we
describe the most common methods of culturing DCs and delivering tumour
antigens and we summarise clinical trials of cancer immunotherapy using DCs-
-based vaccines.
key words: dendritic cells, tumour antigen, immunotherapy
Address for correspondence: Kamila Wojas, Department of Clinical Immunology, Medical University, ul. Jaczewskiego 8, 20–093 Lublin,
Poland, e-mail: kamilawojas@poczta.onet.pl
INTRODUCTION
Dendritic cells are regarded as the most potent
antigen-presenting cells [7]. They possess an extraor-
dinary capacity to capture and process antigen and
contain all that is needed to stimulate T cell immuni-
ty, including high levels of major histocompatibility
complex, co-stimulatory and adhesion molecules [1].
These properties, coupled with the fact that it is now
possible to generate large number of functional DCs
ex vivo, have led to interest in the use of DCs-vac-
cines to induce anti-tumor immunity [1, 7]. The prep-
aration of DC-vaccines consists of a 3-stage process:
the generation of immature DCs from different cell
populations using various stimulators, delivering the
tumour antigens and, finally, the administration of
vaccines to patients [4, 7].
PREPARATION OF DENDRITIC
CELL-BASED VACCINES
Dendritic cells provide a variety of important fea-
tures to generate an immune response, making
them very attractive cells for the immunotherapy
of cancer [2, 8]. A prerequisite for the use of DCs in
therapy is the development of techniques to gen-
erate large numbers of DCs in culture. We can iso-
late DCs precursors from the blood by using densi-
ty-based purification [4, 7]. Circulating immature
DC precursors represent less than 1% of the pe-
ripheral blood mononuclear cells (PBMC). There is
the possibility of amplifying the circulating DCs by treat-
ment donors with Flt3 ligand or GM-CSF [2, 7, 8].
A more effective approach is to culture DCs from
either non-proliferating CD14+ monocytes or pro-
liferating CD34+ precursor cells [2, 4, 7]. CD14+
monocytes can be differentiated into immature
dendritic cells by culture with IL-4 and GM-CSF,
whereas the protocols to produce DCs from CD34+
cells include additional cytokines, such as SCF, Flt3
and TNF-a [7, 8]. Another method of generating
DCs is the use of calcium ionophore (CI), which in-
duces a very rapid differentiation from CD34+ cells,
CD14+ monocytes as well as CML-progenitor cells
to mature DCs [7].
The next step in the preparation of DC-vaccines
is to stimulate dendritic cells by tumour antigen. The
loading of antigen to dendritic cells can be achieved
by several approaches. Many studies have used syn-
thetic peptides as antigens such as Mage-1, Mage-3,
gp-100 and MUC-1 [2, 7]. The advantage of this ap-
proach is a well-defined antigen, which reduces the
possibility of autoimmunity and cross-reactivity and
facilitates in vitro and in vivo monitoring [7]. Due to
the fact that only a few tumour-specific antigens have
been identified, strategies using the whole antigen
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array of the tumour cells have been explored: DCs
can be fed tumour lysates or acid-eluted peptide mix-
tures [2, 7, 8]. Several studies have used apoptotic
tumour cells as an antigen source [7]. The immuno-
genicity of DCs pulsed with apoptotic tumour cells
can be improved by cytokines to improving the func-
tion of DCs (TNF-a, IL-1, IL-6 or CD40L) [7]. The role
of necrotic cells as a source of antigen for DCs re-
mains controversial. Some investigations have shown
that necrotic cells are needed for complete matura-
tion of DCs and therefore provide an obligatory sig-
nal to DCs internalising apoptotic tumour cells [7].
A different strategy for using the whole tumour cell
is the use of DC-tumour hybrids, generated by elec-
trofusion or polyethylene glycol (PEG) treatment [2,
4]. So far allogeneic and autologous DC-tumour hy-
brids have been used in clinical trials. A new method
of delivering tumour antigens is to insert the genes
encoding the tumour-associated antigen (TAA) into
DCs [7]. As vectors the most commonly used are retro-
viral and adenoviral vectors, rarely pox viruses and her-
pes viruses [7]. In some instances cationic lipids and
plasmid-coated gold particles serve as non-viral vec-
tors [7]. Another possibility is to pulse dendritic cells
with tumour-derived mRNA. In the human in vitro sys-
tem, RNA-pulsed DCs were as effective in eliciting an-
tigen-specific responses as peptide-pulsed DCs [7, 8].
Especially in haematological diseases such as CML
and AML, several groups have used DCs arising from
the malignant cells [2, 7, 8]. Since the patological
event occurs in the DC precursor, DCs generated in
vitro or in vivo present the antigens of the tumour
cells. It has been demonstrated that monocyte-de-
rived DCs from CML-patients carry the characteristic
Bcr-Abl antigens and generate CML-specific cytotoxic
responses [7].
CLINICAL TRIALS
OF DENDRITIC CELL VACCINATION
Many clinical DCs vaccination studies have been
initiated or completed. These have focused mostly
on solid tumours, such as melanoma, breast, ovari-
an, renal and prostate cancers, because these tu-
mour-associated antigens are far better defined than
in other tumour types [3, 5, 6]. A series of clinical
trials is beginning in haematological malignancies
such as lymphoma, multiple myeloma and chronic
and acute myelogenous leukemia, where DCs are
cultured from the malignant cells [3, 5]. The recent
therapy described includes glioma patients and gas-
trointestinal patients [3, 6]. These trials have none-
theless established the general safety and feasibility
of this approach, in addition to demonstrating clin-
ical anti-tumour activity [3, 5, 6]. These results have
suggested a broad series of questions about manu-
facturing DCs on a large scale or using tumour anti-
gens regardless of patient haplotype. These issues
should be addressed in future trials.
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